推荐产品
等級
analytical standard
品質等級
化驗
≥98.0% (HPLC)
光學活性
[α]20/D -104±4° in chloroform
儲存期限
limited shelf life, expiry date on the label
技術
HPLC: suitable
gas chromatography (GC): suitable
應用
clinical testing
形式
neat
SMILES 字串
OC(C(C1=O)=CN2C(C1=CC(F)=C3N4CCN(C)CC4)=C3OC[C@@H]2C)=O
InChI
1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
InChI 密鑰
GSDSWSVVBLHKDQ-JTQLQIEISA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
化学结构:喹诺酮
應用
有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务部门。
包裝
无底玻璃瓶。内含物装在插入式熔锥内。
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
其他客户在看
International journal of antimicrobial agents, 48(5), 535-541 (2016-11-05)
Increasing antimicrobial resistance in community-acquired pneumonia (CAP) pathogens has contributed to infection-related morbidity and mortality. Delafloxacin is a novel fluoroquinolone with broad-spectrum activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA). This study aimed to
Pediatrics, 134(1), e146-e153 (2014-06-12)
Safety concerns for fluoroquinolones exist from animal studies demonstrating cartilage injury in weight-bearing joints, dependent on dose and duration of therapy. For children treated with levofloxacin or comparator in randomized, prospective, comparative studies for acute otitis media and community-acquired pneumonia
Drug safety, 33(5), 353-369 (2010-04-20)
The fluoroquinolone class of antibacterial agents are among the most frequently prescribed drugs, with utility in a broad range of bacterial infections. Although very useful agents, the fluoroquinolones as a class are associated with a number of adverse events, some
Drugs, 68(4), 535-565 (2008-03-06)
Levofloxacin (Levaquin) is a fluoroquinolone antibacterial that is the L-isomer of ofloxacin. A high-dose (750 mg) short-course (5 days) of once-daily levofloxacin is approved for use in the US in the treatment of community-acquired pneumonia (CAP), acute bacterial sinusitis (ABS)
American journal of respiratory and critical care medicine, 188(7), 858-864 (2013-08-10)
Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. To compare the effectiveness of
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门